INO 5150

Drug Profile

INO 5150

Alternative Names: INO-5150; Prostate cancer DNA vaccine - Inovio

Latest Information Update: 06 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 12 Dec 2017 Inovio Pharmaceuticals completes a phase I trial for Prostate cancer (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (IM) (NCT02514213)
  • 11 Sep 2017 Immunogenicity data from a phase I trial in Prostate cancer released by Inovio Pharmaceuticals
  • 08 Sep 2017 Updated immunogenicity data from a phase I trial in HIV-1 infections presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top